Cue Biopharma Management

Management criteria checks 3/4

Cue Biopharma's CEO is Dan Passeri, appointed in Aug 2016, has a tenure of 7.67 years. total yearly compensation is $1.37M, comprised of 54.4% salary and 45.6% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth €171.33K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.

Key information

Dan Passeri

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage	54.4%
CEO tenure	7.7yrs
CEO ownership	0.3%
Management average tenure	5.9yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan Passeri's remuneration changed compared to Cue Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$748k	-US$53m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$2m	US$531k	-US$44m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$44m
Dec 31 2020	US$6m	US$501k	-US$45m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$38m
Dec 31 2019	US$1m	US$395k	-US$37m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$43m
Dec 31 2018	US$834k	US$345k	-US$39m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$30m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$410k	US$325k	-US$23m

Compensation vs Market: Dan's total compensation ($USD1.37M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan Passeri (62 yo)

7.7yrs

Tenure

US$1,373,850

Compensation

Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel Passeri	CEO & Director	7.7yrs	US$1.37m	0.28% $ 171.3k
Anish Suri	President & Chief Scientific Officer	5.9yrs	US$1.17m	0.28% $ 172.7k
Kerri-Ann Millar	Chief Financial Officer	5.9yrs	US$1.06m	0.032% $ 19.8k
Ronald Seidel	Co-Founder	no data	US$316.63k	no data
Rodolfo Chaparro	Co-Founder & Senior Advisor	no data	US$316.63k	no data
Steven Almo	Co-Founder and Chairman of Scientific & Clinical Advisory Board	no data	no data	no data
Colin Sandercock	Senior VP	6.3yrs	US$625.51k	no data
Matteo Levisetti	Chief Medical Officer	3.2yrs	no data	0.019% $ 11.7k

5.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 1UC's management team is seasoned and experienced (5.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel Passeri	CEO & Director	7.7yrs	US$1.37m	0.28% $ 171.3k
Steven Almo	Co-Founder and Chairman of Scientific & Clinical Advisory Board	9.3yrs	no data	no data
Frederick Driscoll	Independent Director	5.8yrs	US$143.79k	0% $ 0
Frank Morich	Independent Chairman of the Board	5.8yrs	US$175.29k	0.058% $ 35.6k
Peter Kiener	Independent Director	8.1yrs	US$147.29k	0.00073% $ 452.1
David Baker	Member of Scientific & Clinical Advisory Board	no data	no data	no data
Hidde L. Ploegh	Member of Scientific & Clinical Advisory Board	no data	no data	no data
Rafi Ahmed	Member of Scientific Advisory Board	1.2yrs	no data	no data
Kenneth Pienta	Clinical Advisor	1.3yrs	no data	no data
Abul K. Abbas	Member of Scientific Advisory Board	3.2yrs	no data	no data
Karolina Palucka	Member of Scientific & Clinical Advisory Board	7.2yrs	no data	no data
Michael Kalos	Member of Scientific Advisory Board	3.2yrs	no data	no data

5.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 1UC's board of directors are considered experienced (5.8 years average tenure).

Cue Biopharma Management

Management criteria checks 3/4

Key information

Recent management updates

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought €98k worth of stock

Recent updates

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.11 loss per share (vs US$1.49 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.31 loss in 3Q 2022)

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Market cap size

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.37 loss in 2Q 2022)

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.44 loss in 1Q 2022)

Full year 2022 earnings released: US$1.49 loss per share (vs US$1.41 loss in FY 2021)

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.33 loss in 2Q 2021)

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought €98k worth of stock

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.41 loss in 1Q 2021)

Cue Biopharma, Inc., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.34 loss in 3Q 2020)

Cue Biopharma, Inc. Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Cue Biopharma, Inc Grants U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.38 loss in 2Q 2020)

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

Cue Biopharma to Present A Corporate and Clinical Progress Update At the Upcoming Jefferies Virtual Healthcare Conference

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.48 loss in 1Q 2020)

Cue Biopharma Reports Confirms Partial Response in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Cue Biopharma, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020

Revenue misses expectations

Full year 2020 earnings released: US$1.56 loss per share (vs US$1.67 loss in FY 2019)

Cue Biopharma, Inc. Announces Executive Changes

Cue Biopharma, Inc. Appoints Dr. Matteo Levisetti as Senior Vice President of Clinical Development, Effective February 22, 2021

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA

New 90-day low: €9.95

Independent Director recently bought €70k worth of stock

Cue Biopharma, Inc. Extends Research Collaboration for the Development of Immuno-Stat Biologics for the Treatment of Defined Autoimmune Diseases with Merck

New 90-day low: €10.80

Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

Independent Director recently bought €129k worth of stock

New 90-day low: €12.80

Cue Biopharma, Inc. Announces Appointment of Tamar Howson to Board of Directors

New 90-day low - €15.50

First half earnings released

New 90-day low - €17.90

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age